Show Notes
Could you have metabolic dysfunction even at a normal weight? This episode challenges everything we've been taught about weight and health. Dr. Cooper reveals that up to 25% of normal-weight people have metabolic syndrome, yet they're rarely screened because doctors assume they're healthy based on appearance alone. KEY TAKEAWAYS Weight and metabolic health are not the same thing - you can be metabolically unhealthy at any size
Normal weight people with metabolic dysfunction are often overlooked and undertreated by healthcare providers
Key screening tests include fasting glucose, insulin, HbA1c, triglycerides, HDL cholesterol, blood pressure, and inflammatory markers like HSCRP
Metabolic dysfunction can start in your 20s and take decades to develop into serious disease
Both normal weight and higher weight patients face bias - normal weight people aren't screened enough, while higher weight people have everything blamed on their weight
Early screening and treatment can prevent catastrophic health outcomes later in life
The liver plays a crucial role in metabolism and can become insulin resistant regardless of body weight
NOTABLE QUOTE "You cannot tell anything about someone's health from their outside, what they look like or what, even what they're doing necessarily, but definitely not their body size. So you can be healthy or unhealthy at any size body, and I think that's what's overlooked quite a bit." — Dr. Emily Cooper Links & Resources Podcast Home: fatsciencepodcast.com Cooper Center for Metabolism: coopermetabolic.com Resources from Dr. Cooper: coopermetabolic.com/resources Join Our Community: patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Appendix: Key References Primary literature supporting this episode • Wang et al. Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. Journal of Clinical Endocrinology & Metabolism, 2023. • Review: Beyond BMI — Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Journal of Clinical Medicine, December 2025. • Korean meta-analyses on metabolic dysfunction phenotypes and cardiometabolic risk, Cardiovascular and Metabolic Sciences Journal review, 2024. • Frontiers in Nutrition, January 2026. Associations of metabolic heterogeneity with the progression of cardiometabolic multimorbidity. • International Journal of Obesity, September 2025. Cardiovascular risk factors associated with metabolic health phenotypes. Mechanism references • MASLD — metabolic dysfunction-associated steatotic liver disease — nomenclature and clinical framework. AASLD/EASL consensus, 2023. • Insulin signaling, adipose tissue dysfunction, and ectopic fat deposition — reviews on the upstream-downstream relationship. • Epicardial adipose tissue and cardiovascular dysfunction — Frontiers in Cardiovascular Medicine, January 2026. Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
More from Fat Science
Wondering why weight stalls on treatment? Dr. Emily Cooper explains how the brain defends set points and why eating less stops progress. Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener letters from around the world. The conversation addresses why athletic men with a BMI of 27 can still show high visceral fat on a DEXA scan, how medications defend metabolic set points, and why intentional undereating triggers starvation responses. The team also examines global access to metabolic treatments, dual incretin agonists versus single agonists, artificial sweeteners, and how to interpret two-hour insulin and glucose tolerance curves. Key Takeaways Rapid weight reduction without adequate nutrition can cause lean mass loss and trigger metabolic defense mechanisms. Dual incretin therapies stimulate GIP receptors far more than GLP-1 receptors compared to natural human hormones, creating different patient responses. Intentional calorie restriction reduces natural incretin production and can impair metabolic signaling, making mechanical fueling essential. Fasting insulin suppression combined with pre-diabetes indicators can reflect the brain pulling glucose during periods of low carbohydrate intake. Resources Mentioned Diabesity Foundations Course Cooper Center for Metabolism Diabesity Institute Connect with Us Podcast Home:fatsciencepodcast.com Cooper Center for Metabolism:coopermetabolic.com Diabesity Institute: diabesityinstitute.org Resources from Dr. Cooper:coopermetabolic.com/resources Join Our Community:patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations. Produced by: Podcast Impact Studio https://podcastimpactstudio.com
What do new drug reports really mean for your treatment? Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues. KEY TAKEAWAYS Understanding the difference between efficacy estimand and treatment policy estimand.
Can metabolic dysfunction be the cause of anxiety?
What's the back-to-school metabolism shift all about?